Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction
BACKGROUND: B-type natriuretic peptide (BNP) and the N-terminal fragment of pro-BNP (NT-pro-BNP) are established biomarkers of heart failure. Increased levels of natriuretic peptide (NP) have been associated with poor outcomes in acute exacerbation of COPD (AECOPD); however, most studies did not address the conditions that can also increase NT-pro-BNP levels. We aimed to determine if NT-pro-BNP levels correlate with outcomes of AECOPD in patients without heart failure and other conditions that can affect NT-pro-BNP levels.
METHODS: We conducted a retrospective study in patients hospitalized for AECOPD with available NT-pro-BNP levels and normal left ventricular ejection fraction. We compared patients with normal and elevated NT-pro-BNP levels and analyzed the clinical and outcome data.
RESULTS: A total of 167 of 1,420 (11.7%) patients met the study criteria. A total of 77% of male patients and 53% of female patients had elevated NT-pro-BNP levels (P=0.0031). NT-pro-BNP levels were not associated with COPD severity and comorbid illnesses. Log-transformed NT-pro-BNP levels were positively associated with echocardiographically estimated right ventricular systolic pressure (r=0.3658; 95% confidence interval [CI]: 0.2060-0.5067; P<0.0001). Patients with elevated NT-pro-BNP levels were more likely to require intensive care (63% vs 43%; P=0.0207) and had a longer hospital length of stay (P=0.0052). There were no differences in the need for noninvasive positive pressure ventilation (P=0.1245) or mechanical ventilation (P=0.9824) or in regard to in-hospital mortality (P=0.5273).
CONCLUSION: Patients with AECOPD and elevated NT-pro-BNP levels had increased hospital length of stay and need for intensive care. Based on our study, serum NT-pro-BNP levels cannot be used as a biomarker for increased mortality or requirement for invasive or noninvasive ventilation in this group of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
International journal of chronic obstructive pulmonary disease - 12(2017) vom: 09., Seite 1183-1189 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Adrish, Muhammad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
114471-18-0 |
|---|
| Anmerkungen: |
Date Completed 19.03.2018 Date Revised 09.04.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.2147/COPD.S134953 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271443685 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271443685 | ||
| 003 | DE-627 | ||
| 005 | 20231224232721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/COPD.S134953 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0904.xml |
| 035 | |a (DE-627)NLM271443685 | ||
| 035 | |a (NLM)28458528 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Adrish, Muhammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2018 | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: B-type natriuretic peptide (BNP) and the N-terminal fragment of pro-BNP (NT-pro-BNP) are established biomarkers of heart failure. Increased levels of natriuretic peptide (NP) have been associated with poor outcomes in acute exacerbation of COPD (AECOPD); however, most studies did not address the conditions that can also increase NT-pro-BNP levels. We aimed to determine if NT-pro-BNP levels correlate with outcomes of AECOPD in patients without heart failure and other conditions that can affect NT-pro-BNP levels | ||
| 520 | |a METHODS: We conducted a retrospective study in patients hospitalized for AECOPD with available NT-pro-BNP levels and normal left ventricular ejection fraction. We compared patients with normal and elevated NT-pro-BNP levels and analyzed the clinical and outcome data | ||
| 520 | |a RESULTS: A total of 167 of 1,420 (11.7%) patients met the study criteria. A total of 77% of male patients and 53% of female patients had elevated NT-pro-BNP levels (P=0.0031). NT-pro-BNP levels were not associated with COPD severity and comorbid illnesses. Log-transformed NT-pro-BNP levels were positively associated with echocardiographically estimated right ventricular systolic pressure (r=0.3658; 95% confidence interval [CI]: 0.2060-0.5067; P<0.0001). Patients with elevated NT-pro-BNP levels were more likely to require intensive care (63% vs 43%; P=0.0207) and had a longer hospital length of stay (P=0.0052). There were no differences in the need for noninvasive positive pressure ventilation (P=0.1245) or mechanical ventilation (P=0.9824) or in regard to in-hospital mortality (P=0.5273) | ||
| 520 | |a CONCLUSION: Patients with AECOPD and elevated NT-pro-BNP levels had increased hospital length of stay and need for intensive care. Based on our study, serum NT-pro-BNP levels cannot be used as a biomarker for increased mortality or requirement for invasive or noninvasive ventilation in this group of patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COPD | |
| 650 | 4 | |a NT-pro-BNP | |
| 650 | 4 | |a acute exacerbation of COPD | |
| 650 | 4 | |a natriuretic peptide | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a pro-brain natriuretic peptide (1-76) |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 700 | 1 | |a Nannaka, Varalaxmi Bhavani |e verfasserin |4 aut | |
| 700 | 1 | |a Cano, Edison J |e verfasserin |4 aut | |
| 700 | 1 | |a Bajantri, Bharat |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz-Fuentes, Gilda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of chronic obstructive pulmonary disease |d 2006 |g 12(2017) vom: 09., Seite 1183-1189 |w (DE-627)NLM175408165 |x 1178-2005 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2017 |g day:09 |g pages:1183-1189 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/COPD.S134953 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2017 |b 09 |h 1183-1189 | ||